Cargando…

Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma

PURPOSE: To describe the outcomes of intravitreal injections of bevacizumab for choroidal neovascularization (CNV) associated with choroidal osteoma. METHODS: Retrospective consecutive case series. Three eyes of three patients were studied. All patients were treated with intravitreal injections of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Tadanobu, Takahashi, Kanji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356687/
https://www.ncbi.nlm.nih.gov/pubmed/25784788
http://dx.doi.org/10.2147/OPTH.S78817
_version_ 1782361040812507136
author Yoshikawa, Tadanobu
Takahashi, Kanji
author_facet Yoshikawa, Tadanobu
Takahashi, Kanji
author_sort Yoshikawa, Tadanobu
collection PubMed
description PURPOSE: To describe the outcomes of intravitreal injections of bevacizumab for choroidal neovascularization (CNV) associated with choroidal osteoma. METHODS: Retrospective consecutive case series. Three eyes of three patients were studied. All patients were treated with intravitreal injections of bevacizumab for CNV associated with choroidal osteoma. Best-corrected visual acuity, central foveal thickness, tumor thickness on spectral domain optical coherence tomography, and subretinal pigmentation around the CNV were evaluated. RESULTS: The mean number of intravitreal injections of bevacizumab was 2.0 (range 1–3). The mean follow-up time was 56.0 months (range 25–99 months). The mean LogMAR visual acuity worsened from 0.1 to 0.6. LogMAR visual acuity loss of 0.7 or worse occurred in two of three eyes. CNV was located in the subfoveal area in two eyes, and CNV was located in the juxtafoveal area in one eye. The mean central foveal thickness decreased from 407 μm to 251 μm. The mean tumor thickness decreased from 709 μm to 608 μm. All eyes had subretinal pigmentation around the CNV. CONCLUSION: Intravitreal injections of bevacizumab for subfoveal CNV associated with decalcified choroidal osteoma resulted in poor visual acuity.
format Online
Article
Text
id pubmed-4356687
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43566872015-03-17 Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma Yoshikawa, Tadanobu Takahashi, Kanji Clin Ophthalmol Case Series PURPOSE: To describe the outcomes of intravitreal injections of bevacizumab for choroidal neovascularization (CNV) associated with choroidal osteoma. METHODS: Retrospective consecutive case series. Three eyes of three patients were studied. All patients were treated with intravitreal injections of bevacizumab for CNV associated with choroidal osteoma. Best-corrected visual acuity, central foveal thickness, tumor thickness on spectral domain optical coherence tomography, and subretinal pigmentation around the CNV were evaluated. RESULTS: The mean number of intravitreal injections of bevacizumab was 2.0 (range 1–3). The mean follow-up time was 56.0 months (range 25–99 months). The mean LogMAR visual acuity worsened from 0.1 to 0.6. LogMAR visual acuity loss of 0.7 or worse occurred in two of three eyes. CNV was located in the subfoveal area in two eyes, and CNV was located in the juxtafoveal area in one eye. The mean central foveal thickness decreased from 407 μm to 251 μm. The mean tumor thickness decreased from 709 μm to 608 μm. All eyes had subretinal pigmentation around the CNV. CONCLUSION: Intravitreal injections of bevacizumab for subfoveal CNV associated with decalcified choroidal osteoma resulted in poor visual acuity. Dove Medical Press 2015-03-03 /pmc/articles/PMC4356687/ /pubmed/25784788 http://dx.doi.org/10.2147/OPTH.S78817 Text en © 2015 Yoshikawa and Takahashi. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Series
Yoshikawa, Tadanobu
Takahashi, Kanji
Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
title Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
title_full Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
title_fullStr Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
title_full_unstemmed Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
title_short Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
title_sort long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356687/
https://www.ncbi.nlm.nih.gov/pubmed/25784788
http://dx.doi.org/10.2147/OPTH.S78817
work_keys_str_mv AT yoshikawatadanobu longtermoutcomesofintravitrealinjectionofbevacizumabforchoroidalneovascularizationassociatedwithchoroidalosteoma
AT takahashikanji longtermoutcomesofintravitrealinjectionofbevacizumabforchoroidalneovascularizationassociatedwithchoroidalosteoma